Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (3586)	1/11/2000 11:05:00 AM
From: Waldeen	Respond to of 4140

SurgiLight Inc., (OTCBB:SRGL - news) biz.yahoo.com Source is above, article follows: Tuesday January 11, 9:48 am Eastern Time Company Press Release SurgiLight Submitted a Clinical Trial Protocol to Mt. Sinai Hospital in New York for a New Laser Procedure for Presbyopia Reversal ORLANDO, Fla.--(BUSINESS WIRE)--Jan. 11, 2000--SurgiLight Inc., (OTCBB:SRGL - news) announced today that it had submitted a clinical trial Protocol to Mt. Sinai Hospital in New York City for a new procedure called Laser Presbyopia Reversal (LPR). Presbyopia is a vision problem caused by age and affects over 900 million worldwide for those over the age of 45. The Company believes that the potential procedure market for presbyopia correction is estimated to be over $150 billion in US and over $1,500 billion worldwide. The first group of clinical results of this new procedure for laser presbyopia correction was reported by the Company at 1999 Fall World Refractive Surgery Symposium, Oct. 21-23, in Orlando, Fla. The Company is currently treating patients ranging in age from 44 to 65 in Venezuela. Clinical trials in US and other countries may start by mid 2000. An IDE clinical submission in US will be filed to the Food and Drug Administration (FDA) after the IRB approval from Mt. Sinai Hospital. The Company believes that its new presbyopia infrared (IR) laser will offer a procedure that cannot normally be achieved by other IR lasers using mono-vision, hyperopic correction made by Ceramoptec GmbH (in Germany), and Sunrise Technologies International (Nasdaq:SNRS - news). It also believes that its new IR laser may offer advantages over non-laser methods including faster, more precise and less regression after the surgery. In addition, the Company's new infrared lasers for the treatment of presbyopia and LASIK may be safer, with less mutagenic effects, than the existing ultraviolet excimer lasers currently made by Visx (Nasdaq:VISX - news), Summit Technology (Nasdaq:BEAM - news), LaserSight (Nasdaq:LASE - news). SurgiLight believes that it will be the first company to introduce this new technology into the laser vision market. SurgiLight also believes that its ``cold' IR (3 microns) laser, used for LASIK and presbyopia correction, is fundamentally different when compared with the ``thermal' IR (2 micron) laser made by Sunrise (Nasdaq:SNRS - news), used for hyperopia correction. SurgiLight believes that its patent pending IR laser technology will generate long term recurring income from procedure royalty fees without incurring patent and licensing fees payable to IBM (NYSE:IBM - news), Visx and Summit which only apply to UV Excimer lasers. SurgiLight is a world leader for the development of new infrared laser technologies, a pioneer and inventor of scanning lasers and laser presbyopia reversal. The Company continues to receive royalty income from its Laser Eye Centers and Cosmetic Mobile Centers This press release may contain forward-looking statements regarding future events and performance of the Company, which involves risks and uncertainties that could materially affect actual results. Investors should refer to documents that the Company files with the SEC for a description of certain factors that could cause actual results to vary from current expectations and the forward-looking statements contained in this press release. -------------------------------------------------------------------------------- Contact: SurgiLight Inc., Winter Park, Fla. Dr. Lin, 407/482-4555, Email: surgilight@aol.com